Lexeo Therapeutics, Inc. Common Stock
LXEO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.04 | -0.03 | 0.17 |
| FCF Yield | -7.37% | -15.60% | -18.90% | -13.01% |
| EV / EBITDA | -18.87 | -5.82 | -2.97 | -7.59 |
| Quality | ||||
| ROIC | -16.74% | -20.86% | -34.67% | -21.60% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.46 | 1.04 | 0.66 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -9.18% | -25.84% | 23.30% | -58.27% |
| Safety | ||||
| Net Debt / EBITDA | 1.65 | 1.04 | 0.61 | 0.99 |
| Interest Coverage | -984.00 | -520.14 | -1,207.32 | -912.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -790.64 | -3,533.82 | 0.00 | 0.00 |